[{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"4332101d-7ce0-4281-baf4-5b9d31806fda","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303519","created_at":"2022-03-31T17:52:38.349Z","updated_at":"2024-07-02T16:35:29.269Z","phase":"Phase 2","brief_title":"Safusidenib Phase 2 Study in IDH1 Mutant Glioma","source_id_and_acronym":"NCT05303519","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668 • safusidenib (DS-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-11-14"},{"id":"9f163179-7969-4e4d-b007-578f94b3dff7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092934","created_at":"2021-01-18T15:14:15.728Z","updated_at":"2024-07-02T16:36:28.360Z","phase":"Phase 1/2","brief_title":"A Study of AK-01 (LY3295668) in Solid Tumors","source_id_and_acronym":"NCT03092934","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 05/29/2017","start_date":" 05/29/2017","primary_txt":" Primary completion: 04/20/2020","primary_completion_date":" 04/20/2020","study_txt":" Completion: 04/20/2020","study_completion_date":" 04/20/2020","last_update_posted":"2021-07-02"},{"id":"a7da3916-76a1-444e-b30b-8aa44cb85184","acronym":"","url":"https://clinicaltrials.gov/study/NCT03955939","created_at":"2021-01-18T19:28:11.364Z","updated_at":"2024-07-02T16:36:44.594Z","phase":"Phase 1b","brief_title":"A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body","source_id_and_acronym":"NCT03955939","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668 • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 05/14/2020","primary_completion_date":" 05/14/2020","study_txt":" Completion: 05/14/2020","study_completion_date":" 05/14/2020","last_update_posted":"2020-06-01"},{"id":"7e7b04d9-e565-43cc-8e36-d98ef6492da9","acronym":"PARICCA","url":"https://clinicaltrials.gov/study/NCT02651415","created_at":"2021-01-18T12:54:31.496Z","updated_at":"2025-02-25T17:22:58.794Z","phase":"Phase 2","brief_title":"Phase II Study of Perindopril and Regorafenib in mCRC","source_id_and_acronym":"NCT02651415 - PARICCA","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • LY3295668"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 11/07/2018","study_completion_date":" 11/07/2018","last_update_posted":"2019-09-12"}]